

8:30 am EDT - 2:30 pm EDT
Past Event
8:30 am - 2:30 pm EDT
1775 Massachusetts Avenue NW
Washington, DC
20036
As the prevalence of drug-resistant bacteria continues to rise, there is a pressing need for new drugs to combat infections by these organisms. However, research and development in this area has slowed, creating a public health concern that we lack the drugs necessary to treat multi-drug resistant infections. Challenges to promoting antibacterial drug development may be scientific, methodological, regulatory, or economic in nature.
On Wednesday, May 9, 2012, the Engelberg Center for Health Care Reform convened an expert workshop, “Facilitating Antibacterial Drug Development,” that explored solutions to methodological and regulatory challenges that could make the development process more efficient. This meeting brought together diverse multi-stakeholder experts—including medical product developers, health care professionals, researchers, patient advocates, representatives of the U.S. Food and Drug Administration, and other groups—to explore the following issues:
For more information on FDA’s Antibacterial Drug Development Task Force, click here.
Sherry Glied, Richard G. Frank
April 21, 2025
Marta Wosińska
April 21, 2025
Darrell M. West
April 17, 2025